PMID- 35284968
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20220516
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 42
IP  - 5
DP  - 2022 May
TI  - The impact of anti-endothelial cell antibodies (AECAs) on the development of 
      blood vessel damage in patients with systemic lupus erythematosus: the 
      preliminary study.
PG  - 791-801
LID - 10.1007/s00296-022-05104-5 [doi]
AB  - Vascular injury represents one of the most frequent lesions in systemic lupus 
      erythematosus (SLE). The aim of the study was to assess the influence of 
      anti-endothelial cell antibodies (AECAs) on the development of endothelial cell 
      (EC) activation, dysfunction and subsequent vasculitis in women with SLE. Fifty 
      six women with SLE were divided into 2 subgroups, i.e. subjects with positive 
      AECAs (+) and those with negative AECAs (-). The control group consisted of 25 
      healthy women. Clinical characteristics, routine laboratory tests and circulating 
      markers of EC activation/dysfunction, i.e. monocyte-chemotactic protein-1 
      (MCP-1), soluble E- and P-selectin, vascular and intercellular adhesion 
      molecule-1 (sVCAM-1, sICAM-1), von Willebrand factor (vWF), pentraxin 3 (the 
      marker of vasculitis) the indicator of procoagulant activity i.e. prothrombin 
      fragment 1 + 2 (F1 + 2) were detected using ELISA and compared between patients 
      with AECA (+), AECA (-) and control subgroups. Serum concentrations of AECAs in 
      AECA(+), AECA(-) and control groups were 4.58 +/- 2.97, 0.92 +/- 0.50 and 0.72 +/- 0.28 
      AU/ml, respectively (p < 0.001). The study showed significant increases in EC 
      activation markers, i.e. MCP-1, sE-selectin, sVCAM-1 and F1 + 2 in SLE AECA(+) 
      compared to SLE AECA(-) and control groups. However, the indicator of vasculitis 
      (PTX3) was significantly lower in SLE AECA(+). Moreover, multivariate analysis of 
      variance showed a positive correlation between AECAs and sE-selectin and sVCAM-1 
      levels, but not with PTX3. AECAs were involved in the initial stages of vascular 
      damage in SLE, i.e. in EC activation and dysfunction. However, they did not play 
      a role in the development of vasculitis.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Cieslik, Pawel
AU  - Cieslik P
AUID- ORCID: 0000-0002-3723-3591
AD  - Department of Internal, Autoimmune and Metabolic Diseases, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, ul. Medykow 14, 40-752, 
      Katowice, Poland. pawelcie@mp.pl.
FAU - Semik-Grabarczyk, Elzbieta
AU  - Semik-Grabarczyk E
AUID- ORCID: 0000-0002-7871-528X
AD  - Department of Internal, Autoimmune and Metabolic Diseases, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, ul. Medykow 14, 40-752, 
      Katowice, Poland.
FAU - Hrycek, Antoni
AU  - Hrycek A
AD  - Department of Internal, Autoimmune and Metabolic Diseases, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, ul. Medykow 14, 40-752, 
      Katowice, Poland.
FAU - Holecki, Michal
AU  - Holecki M
AUID- ORCID: 0000-0002-3289-1050
AD  - Department of Internal, Autoimmune and Metabolic Diseases, Faculty of Medical 
      Sciences in Katowice, Medical University of Silesia, ul. Medykow 14, 40-752, 
      Katowice, Poland.
LA  - eng
PT  - Journal Article
DEP - 20220314
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (anti-endothelial cell antibody)
SB  - IM
MH  - Autoantibodies
MH  - Biomarkers
MH  - Endothelium, Vascular
MH  - Female
MH  - Humans
MH  - *Lupus Erythematosus, Systemic
MH  - *Vasculitis/pathology
OTO - NOTNLM
OT  - Anti-endothelial cell antibodies
OT  - Endothelial cell activation markers
OT  - Systemic lupus erythematosus
OT  - Vasculitis
EDAT- 2022/03/15 06:00
MHDA- 2022/04/16 06:00
CRDT- 2022/03/14 06:02
PHST- 2021/11/25 00:00 [received]
PHST- 2022/02/10 00:00 [accepted]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
PHST- 2022/03/14 06:02 [entrez]
AID - 10.1007/s00296-022-05104-5 [pii]
AID - 10.1007/s00296-022-05104-5 [doi]
PST - ppublish
SO  - Rheumatol Int. 2022 May;42(5):791-801. doi: 10.1007/s00296-022-05104-5. Epub 2022 
      Mar 14.